Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Aggen

Medical Oncology New York, NY Medical Doctor

NPI 1194168955 CMS profile 4226107

353 E 68Th St, New York, NY 10065

Open in the dashboard

General payments

$52,864

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,034,011 paid to institutions, not to them · program years 2022–2025

Through program year 2025, David Aggen of New York, NY is reported in the CMS Open Payments database as having received $52,864 across 72 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,034,011 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,044 14
2024 General $22,960 22
2023 General $8,884 15
2022 General $4,624 6
2021 General $5,377 4
2019 General $976 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Aggen
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to David Aggen were reported at $10,044. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year David Aggen Medical Oncology median Middle half National median
2019 $976 $968 $140–$6,658 $163
2020 $0 $747 $102–$5,891 $114
2021 $5,377 $430 $50–$4,098 $132
2022 $4,624 $812 $127–$4,907 $149
2023 $8,884 $957 $144–$5,248 $160
2024 $22,960 $1,042 $149–$5,650 $164
2025 $10,044 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $18,491 16 payments
  2. Seattle Genetics, Inc. $15,879 20 payments
  3. Eisai Inc. $5,969 7 payments
  4. Astellas Pharma US Inc $4,800 1 payment
  5. E.R. Squibb & Sons, L.L.C. $2,940 5 payments
  6. F. Hoffmann-La Roche AG $1,861 6 payments
  7. GlaxoSmithKline, LLC. $1,450 1 payment
  8. AstraZeneca Pharmaceuticals LP $1,338 15 payments
  9. Exelixis Inc. $137 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $28,741 11 payments
  2. Honoraria $16,800 1 payment
  3. Food and Beverage $4,487 47 payments
  4. Travel and Lodging $2,836 13 payments
Products named General payments · program years 2019–2025
  1. Padcev Oncology $17,647 10 payments
  2. PADCEV Oncology $15,766 19 payments
  3. Lenvima $5,969 7 payments
  4. PADCEV Oncology $4,800 1 payment
  5. XTANDI $568 4 payments
  6. ORGOVYX $568 4 payments
  7. LYNPARZA $374 4 payments
  8. OPDIVO $340 3 payments
  9. TALZENNA $290 2 payments
  10. CABOMETYX $137 1 payment
  11. Other $5 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

447

Median for Internal Medicine: 777

Drug cost

$1,875,420

Median for Internal Medicine: $73,373

Branded share of claims

22.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cabometyx Cabozantinib S-Malate Brand 38 $723,877
Inlyta Axitinib Brand 25 $416,278
Fotivda Tivozanib Hcl Brand 11 $312,006
Lenvima Lenvatinib Mesylate Brand 12 $252,489
Abiraterone Acetate Generic 20 $91,241
Orgovyx Relugolix Brand 15 $39,665
Everolimus Generic 19 $37,149
Ondansetron Hcl Generic 48 $622
Dexamethasone Generic 30 $548
Triamcinolone Acetonide Generic 15 $303

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$83,784

Medicare's payments for the services billed

Medicare patients

192

Average age 75

Services billed

944

52 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 73%
Arthritis 51%
Chronic kidney disease 49%
Ischemic heart disease 41%
Diabetes 33%
Atrial fibrillation 26%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Padcev
  • PFIZER INC. $17,576
$17,576 — —
Lenvima
  • Eisai Inc. $2,945
$2,945 12 —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $223
$223 — —
CABOMETYX
  • Exelixis Inc. $137
$137 38 —
XTANDI
  • PFIZER INC. $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record